Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Bronchiolitis Obliterans Syndrome 2Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Blast Crisis 1

Interventions

ibrutinib 2fludarabine 2asciminib 2Sirolimus 2Mycophenolic Acid 2Cyclophosphamide 2ruxolitinib 1axatilimab 1Whole-Body Irradiation 1Specimen Handling 1Panobinostat 1Mesna 1Filgrastim 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × asciminib × 90 days × Clear all
NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06427811 2026-04-17

ASC4INDIA

Novartis

Phase 4 Completed
85 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡